Fetal Bovine Serum Market by Application (Biopharmaceuticals, Cell Culture, Human & Animal Vaccine Production, and Others) and End User (Biotechnology & Pharmaceutical Company, Academic Institute, and Research Laboratory): Global Opportunity Analysis and Industry Forecast, 20182025
- Published Date: 2020-10-18
- Report ID: 3502
- Pages: 219
-
Format:
The global fetal bovine serum market was valued at $695 million in 2017 and is estimated to reach at $1,037 million by 2025, registering a CAGR of 5.1 % from 2018 to 2025.
Fetal bovine serum (FBS) is an ideal growth medium containing several nutrients and optimal combination of growth factors, which make it the most effective growth promoter for almost any cell culture system. In addition, the significantly lower content of antibodies compared to adult and newborn sera minimizes the risk of antibody cross-reaction with cells in culture. FBS finds its application in animal tissue culture and plant tissue culture, while reagents are used in various biotechnology applications such as diagnosis, laboratory research, drug development, and others.
Significant rise in biotechnological R&D pertaining to the introduction of novel biopharmaceuticals has led to an increase in demand for FBS. Moreover, increase in investments and funding for research interventions in both developed and developing countries boost the market growth. However, ethical & scientific concerns associated with the potential misuse of biotechnology research practices and dearth of skilled personnel hamper the market growth. Few fraud cases associated with the production of fetal bovine sera have been reported, which further restrains the growth of the market. Conversely, untapped potential of the emerging economies such as India, China, and others is anticipated to provide lucrative opportunities to the key players involved in the fetal bovine serum market.
The fetal bovine serum media market is segmented based on application, end user, and region. The applications covered in the study include biopharmaceuticals, cell culture, human and animal vaccine production, and others. Depending on end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, and research laboratory. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global fetal bovine serum market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the global trends in the fetal bovine serum market.
Key players and their strategies are provided to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Application
o Biopharmaceuticals
o Cell Culture
o Human & Animal Vaccine Production
o Others
By End User
o Biotechnology & Pharmaceutical Companies
o Academic Institute
o Research Laboratory
By Region
o North America
U.S.
Canada
Mexico
o Europe
UK
France
Germany
Italy
France
Rest of Europe
o Asia-Pacific
Japan
China
India
South Korea
Australia
Rest of Asia-Pacific
o LAMEA
Saudi Arabia
South Africa
Brazil
Rest of LAMEA
KEY MARKET PLAYERS
GE Healthcare
Merck KGaA (Sigma Aldrich)
HiMedia Laboratories Pvt., Ltd.
Bio-Techne
Biowest
Biological Industries
Atlas Biologicals
Rocky Mountain Biologicals
PAN-Biotech.
Thermo Fisher Scientific Inc.
The other players in the value chain include (profiles not included in the report)
Takara Bio, Inc.
Cyagen Biosciences
Tissue Culture Biologicals
Bovogen Biologicals Pty Ltd.
TCS Biosciences Ltd.
Corning Incorporated
Access Biologicals
Caisson Laboratories, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. Key findings
2.2.1. Top impacting factors
2.2.2. Top investment pockets
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Parent/Peer Market Overview
3.3. Key Forces Shaping Fetal Bovine Serum Industry/Market
3.3.1. Low bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Moderate Threat of Substitution
3.4. Pricing Analysis
3.4.1. Pricing Analysis of Fetal Bovine Serum, By Region, 2018 & 2025
3.5. Market evolution/ Industry roadmap
3.6. Value Chain Analysis
3.7. Impact of government regulations on global fetal bovine serum market
3.8. Industry Pain point analysis
3.9. Case Studies
3.9.1. Case Study 01
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Rise in R&D Investment
3.10.1.2. High demand of fetal bovine sera
3.10.1.3. Surge in biopharmaceutical production
3.10.2. Restraints
3.10.2.1. High price
3.10.2.2. Increased use of alternatives
3.10.3. Opportunities
3.10.3.1. Untapped potential of the emerging economies
CHAPTER 4: FETAL BOVINE SERUM MARKET, BY APPLICATION
4.1. Overview
4.2. Biopharmaceuticals
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Cell Culture
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Human and Animal Vaccine Production
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
CHAPTER 5: FETAL BOVINE SERUM MARKET, BY END USER
5.1. Overview
5.2. Biotechnology & Pharmaceutical Company
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Academic Institute
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Research Laboratory
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: FETAL BOVINE SERUM MARKET, BY REGION
6.1. Overview
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast, by application
6.2.3. Market size and forecast, by end user
6.2.4. Market analysis by country
6.2.4.1. U.S. Market size and forecast, by application
6.2.4.2. Market size and forecast, by end user
6.2.4.3. Canada
6.2.4.4. Canada Market size and forecast, by application
6.2.4.5. Canada Market size and forecast, by end user
6.2.4.6. Mexico Market size and forecast, by application
6.2.4.7. Mexico Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by application
6.3.3. Europe Market size and forecast, by end user
6.3.4. Europe Market size and forecast, by country
6.3.4.1. UK Market size and forecast, by application
6.3.4.2. UK Market size and forecast, by end user
6.3.4.3. Germany Market size and forecast, by application
6.3.4.4. Germany Market size and forecast, by end user
6.3.4.5. France Market size and forecast, by application
6.3.4.6. France Market size and forecast, by end user
6.3.4.7. Italy Market size and forecast, by application
6.3.4.8. Market size and forecast, by end user
6.3.4.9. Spain Market size and forecast, by application
6.3.4.10. Spain Market size and forecast, by end user
6.3.4.11. Rest of Europe Market size and forecast, by application
6.3.4.12. Rest of Europe Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by application
6.4.3. Market size and forecast, by end user
6.4.4. Market size and forecast, by country
6.4.4.1. China Market size and forecast, by application
6.4.4.2. China Market size and forecast, by end user
6.4.4.3. India Market size and forecast, by application
6.4.4.4. India Market size and forecast, by end user
6.4.4.5. Japan Market size and forecast, by application
6.4.4.6. Japan Market size and forecast, by end user
6.4.4.7. South Korea Market size and forecast, by application
6.4.4.8. South Korea Market size and forecast, by end user
6.4.4.9. Australia Market size and forecast, by application
6.4.4.10. Australia Market size and forecast, by end user
6.4.4.11. Rest of Asia-Pacific Market size and forecast, by application
6.4.4.12. Rest of Asia-Pacific Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by application
6.5.3. Market size and forecast, by end user
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil Market size and forecast, by application
6.5.4.2. Brazil Market size and forecast, by end user
6.5.4.3. Saudi Arabia Market size and forecast, by application
6.5.4.4. Saudi Arabia Market size and forecast, by end user
6.5.4.5. Saudi Arabia Market size and forecast, by application
6.5.4.6. Saudi Arabia Market size and forecast, by end user
6.5.4.7. Rest of LAMEA Market size and forecast, by application
6.5.4.8. Rest of LAMEA Market size and forecast, by end user
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. INTRODUCTION
7.1.1. MARKET PLAYER POSITIONING, 2018
7.2. MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018 (%)
7.3. TOP WINNING STRATEGIES
7.4. COMPETITIVE DASHBOARD
7.5. COMPETITIVE HEATMAP
CHAPTER 8: COMPANY PROFILES: FETAL BOVINE SERUM MARKET
8.1. BIO-TECHNE (ATLANTA BIOLOGICS)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. SERA SCANDIA A/S (BIOWEST
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. PAN-BIOTECH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. HIMEDIA LABORATORIES PVT., LTD
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. BIOLOGICAL INDUSTRIES
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. ATLAS BIOLOGICALS
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Merck KGAA (SIGMA ALDRICH)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. ROCKY MOUNTAIN BIOLOGICALS (RMBIO)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. THERMO FISHER SCIENTIFIC INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
8.11. Other Key Player Profile
8.11.1. Key player snapshot
CHAPTER 9: APPENDIX
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
